Latest to produce a ‘nanotechnology industry’ index are San Francisco’s Global Crown Capital, which is claimed to be “the industry’s first pure play nanotechnology index.”
The companies comprising the index, as well as their descriptions are listed below. Given the similarities between all of these indices, and the small number of publicly traded stocks that have much of a nanotech component (GCC have excluded the likes of IBM) it must have taken all morning to come up with the index.
Meanwhile the Lux nanotech index makes “Stupid Investment of the Week“, although who is stupider, investors thinking that nanotech has any influence whatsoever on the stock price of General Motors, or those who want pure-play nanotech investments is an open question.
Accelrys Inc. (ACCL)
Accelrys engages in the delivery of computational science and informatics software, developed internally or collaborated and partnered with leading academic and industrial scientists, and other technology vendors, to world’s leading pharmaceutical, chemical, biotechnology, nanotechnology, academic, and government research organizations. Accelrys delivers scientific software solutions that transform the process of discovering and developing drugs and materials from experiment-driven to software-driven. Accelrys does this by enabling solutions via an open integration platform and an open business model.
Acusphere Inc. (ACUS)
Acusphere, Inc. is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary porous microparticle technology. It is focused on developing proprietary drugs that can offer significant benefits such as improved safety and efficacy, increased patient compliance, greater ease of use, expanded indications or reduced cost. The companyâ€™s three initial product candidates are designed to address large unmet clinical needs within cardiology, oncology and asthma. Its lead product candidate is a cardiovascular drug in Phase III clinical development for the detection of coronary heart disease, the leading cause of death in the United States.
Affymetrix Inc. (AFFX)
Affymetrix scientists invented the world’s first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been shipped around the world. Affymetrix’ patented photolithographic manufacturing process provides the information capacity on an array that enables researchers to use a whole-genome approach to analyze the relationship between genetics and health
Altair Nanotechnologies Inc. (ALTI)
Altair Nanotechnologies owns a proprietary technology for making nanocrystalline materials of unique characteristics, economically and in large quantities. The company produces closely-sized nanoparticles of titanium dioxide and other ceramic oxide materials and compounds. Applications are found in products such as advanced batteries, fuel cells, thermal spray coatings, specialty paints, catalysts, plastics, cosmetics, solar cells and self-cleaning and sanitizing materials. In line with its cutting-edge position in nanotechnology, Altair Nanotechnologies is also designing materials to suit the nanoparticle applications of the future.
Arrowhead Research Corp. (ARWR)
Arrowhead Research is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy. Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial, and operational support. Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology.
BioDelivery Sciences International Inc. (BDSI)
Biodelivery Sciences International is a specialty biopharmaceutical company developing selected drug delivery technologies with significant outlicenses in addition to an exciting proprietary pipeline. Bioralâ„¢ technology, the most clinically-advanced nanotechnology for drug delivery, provides oral delivery of injectables, and enhances the efficacy and reduces the toxicity of certain oral drugs by favorably altering biodistribution. BEMAâ„¢ technology enables transmucosal membrane administration of drugs where rapid onset of action is desirable such as pain and nausea and vomiting.
Biosante Pharmaceuticals Inc. (BPA)
BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante’s hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis. The company also is developing its proprietary calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems.
FEI Co. (FEIC)
FEI Company’s Tools for Nanotech(TM), featuring focused ion- and electron-beam technologies, deliver 3D characterization, analysis and modification capabilities with resolution down to the sub-Angstrom level and provide innovative solutions for customers working in NanoResearch, NanoElectronics and NanoBiology. The company’s products for NanoElectronics address a robust set of both fab- and lab-based applications including 3D metrology and defect analysis, mask repair and circuit edit. FEI is bringing the nanoscale within the grasp of leading researchers and manufacturers and helping to turn ideas into reality.
Flamel Technologies SA (FLML)
Flamel Technologies is a drug delivery company with expertise in polymer chemistry. The company has invented two innovative polymer-based technologies: MicropumpÂ® for the delivery of small molecule drugs, including pediatric and geriatric uses and MedusaÂ® for the delivery of native protein drugs. Flamel provides tailored solutions to the industry and turns already-marketed or new drugs into more effective and safer medicines.
Immunicon Corp. (IMMC)
Immunicon is developing and commercializing cell- and molecular-based diagnostic and research products for rare cell analysis, with an initial focus on cancer. Reagent kits incorporating Immunicon proprietary technology are used with the companyâ€™s instrument systems to capture, count and characterize circulating tumor cells or circulating endothelial cells from whole blood. Immunicon believes its technology may be applied to other fields of medicine beyond cancer including cardiovascular and inflammatory diseases as well as drug development and life science research.
JMAR Technologies Inc. (JMAR)
JMAR Technologies, Inc. is an innovator in the development of laser-based equipment for imaging, analysis and fabrication at the nano-scale. The Company is leveraging over a decade of laser and photonics research to develop a diverse portfolio of products with commercial applications in rapidly growing industries while continuing to carry out research and development for the U.S. Defense Advanced Research Projects Agency (DARPA) and support for the U.S. Government’s Defense Microelectronics Activity (DMEA) semiconductor fabrication facility. JMAR is targeting the nanotechnology, bioscience and semiconductor industries with its Britelightâ„¢ Laser; X-ray Light Source; Compact X-ray Microscope – for 3D visualization of single cells and polymers – and its X-ray Nano Probe – enabling interaction, analysis and materials modification at the nano-scale. JMAR also develops, manufactures and markets its BioSentryâ„¢ microorganism early warning system and maintains a strategic alliances for the production of the READ chemical sensor for homeland security, environmental and utility infrastructure industries.
Nanophase Technologies Corp. (NANX)
Nanophase Technologies is a nanocrystalline materials innovator and manufacturer with an integrated family of nanomaterial technologies. The entire focus of Nanophase is nanotechnology, with two distinct and patented processes for the preparation and commercial manufacturing of nanopowder metal oxides i.e. Aluminum Oxide, Zinc Oxide, Cerium Oxide, Titanium Dioxide, and several others. Nanophase Technologies Corporation has developed a process, Discrete Particle Encapsulation, to coat the surface of its nanoparticles with a thin polymeric shell that enables compatibility of the particles with a wide variety of fluids, resins and polymers. Also, Nanophase has developed technology to permit the dispersion of its nanoparticles in water and a variety of polar and non-polar organic fluids. This allows Nanophase to supply concentrated, ready-to-use nanoparticle dispersions, eliminating the need for customers to disperse the nanoparticles themselves. Nanophaseâ€™s family of integrated technologies economically produces nanocrystalline materials, and then nanoengineers those materials to fit a customer need.
Novavax Inc. (NVAX)
Novavax, Inc. is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on drug delivery and biological technologies. The Company currently sells, markets and distributes a line of women’s health prescription pharmaceuticals, including ESTRASORBÂ®, the first topical emulsion for estrogen therapy. Novavax also focuses on developing its Virus Like Particle (VLP) technology into vaccines for the prevention of infectious diseases such as HIV/AIDS, pandemic flu, seasonal flu and SARS. Additionally, its biologicals division is developing E-selectin tolerogen in conjunction with the National Institute of Neurological Disorders and Stroke for the prevention of illness where inflammatory and immune responses are involved.
NVE Corp. (NVEC)
NVE Corporation develops and sells devices using “spintronics,” a nanotechnology it helped pioneer, which utilizes electron spin rather than electron charge to acquire, store and transmit information. The company is also a licensor of spintronic magnetic random access memory technology (MRAM), which it believes has the potential to revolutionize electronic memory. NVE also manufactures high-performance spintronic products including sensors and couplers which are used to acquire and transmit data in automated factories.
SkyePharma plc (SKYE)
Skyepharma is able to solve the industry’s formulation and delivery challenges by drawing on the range of drug delivery technologies, turning already-proven drugs into more effective and safer medicines. Combining its established pre-clinical, clinical and regulatory expertise with the capability to formulate and manufacture drugs, both for clinical studies and commercial sale, Skyepharma identifies and develops new therapeutics for itself and for its partners.
Harris & Harris Group, Inc. (TINY)
Harris & Harris Group, Inc. is a publicly held venture capital company, and it has chosen to operate in a Business Development Company structure primarily because it is the regulatory framework for publicly held companies specifically created to facilitate making venture capital investments in early stage companies commercializing proprietary intellectual property. This structure also permits the Company to manage its business in a more tax-advantaged manner for its shareholders. Since August of 2001, Harris & Harris Group has made all of its initial investments in tiny technology. Tiny technology includes nanotechnology, microsystems and microelectromechanical systems (MEMS).
Veeco Instruments Inc. (VECO)
Veeco is a provider of Metrology (used to measure at the nanoscale) and Process Equipment (helps to create nanoscale devices) solutions used by manufacturers in the data storage, semiconductor and compound semiconductor/wireless industries. These industries help create a wide range of information age technology and products, such as personal computers and network servers, as well as newer technologies such as television set-top boxes, personal digital assistants and other consumer products. Veecoâ€™s products are also critical enabling instruments used in the advancement of scientific research and nanotechnology.
Orthovita Inc. (VITA)
Orthovita is a biomaterials company with proprietary technologies applied to the development of BioStructures, synthetic biologically active tissue engineering products for restoration of the human skeleton. Its focus is on developing novel products for use in spine surgery and in the repair of osteoporotic fractures. The company is also addressing a broad range of clinical needs in the trauma market.
Westaim Corp. (WEDX)
Westaim Corporation has developed technologies in nanotechnology (NUCRYST Pharmaceuticals) and flat panel televisions (iFire Technology). Westaimâ€™s strategy is to partner with established commercial leaders for effective market penetration of its technologies. NUCRYST Pharmaceuticals first products are for wound care dressings for life-threatening or serious burns and chronic wounds. NUCRYST is actively developing new pharmaceutical products including its first dermatology drug that is based on its platform nanocrystalline silver technology. iFire Technology’s goal is to be the first company to produce a truly affordable large sized, flat panel high definition television using its proprietary thick-film dielectric electroluminescent (TDEL) technology.